Nuwellis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 29, 2026, for Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company. The filing details a private placement of securities, a warrant inducement transaction, the acquisition of assets via Rendiatech, Ltd., and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Gross proceeds of approximately $3.1 million from the sale of 994,537 pre-funded warrants and 1,989,074 common warrants at a combined price of $3.09 per unit.
- Warrant Inducement Proceeds: Gross proceeds of approximately $2.0 million from the exercise of existing warrants at a reduced price of $2.84 per share.
- Shares Issued: Approximately 623,585 shares of Common Stock issued from the warrant inducement exercise (subject to beneficial ownership blockers).
- Outstanding Shares: As of January 29, 2026, the Company had 1,686,892 shares of common stock issued and outstanding.
- Transaction Costs: Placement agent fees of 8.0% of gross proceeds for both the Private Placement and Warrant Inducement, plus reimbursement of up to $90,000 in out-of-pocket expenses for the Private Placement.
- Debt and Liquidity: The filing does not provide specific balance sheet data regarding total debt or cash on hand. Proceeds are designated for working capital and general corporate purposes.
Material Changes and Transactions
- Acquisition of Rendiatech: Entered into an agreement to acquire Rendiatech, Ltd., an Israeli entity holding assets from RenalSense Ltd. (bankruptcy proceedings).
- Consideration: $125,000 cash at closing, 150,000 shares of Common Stock, and options to purchase 30,000 shares.
- Future Payments: $125,000 due by December 31, 2026; $250,000 due by the earlier of commercial regulatory clearance or December 31, 2027.
- Earn-Out: 9% royalty on gross sales of "Clarity RMS" and "Clarity Prime" products until aggregate payments reach $2.0 million.
- Executive Appointment: Carisa Schultz appointed as Chief Financial Officer, effective February 2, 2026.
- Compensation: $265,000 annual base salary and a bonus of up to 40% of base salary.
Outlook, Risks, and Contingencies
- Closing Conditions: The Rendiatech transaction is contingent upon approval from the Israeli Tax Authority and other customary closing conditions.
- Registration Rights: The Company must file registration statements for the resale of Private Placement securities within 15 days and for the January Inducement Warrants within 15 days of closing.
- Blackout Periods: The Company is restricted from issuing new equity or entering into variable rate transactions for 45 days following the effective date of the registration statement (or 3 months for variable rate transactions).
- Beneficial Ownership Limitations: Warrant exercises are subject to a 4.99% beneficial ownership limitation (electable up to 9.99%), which may limit the number of shares issued to the purchaser.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 8% placement fees and expenses.
- Confirm the status of the Israeli Tax Authority approval required for the Rendiatech acquisition.
- Review the full text of the Registration Rights Agreement (Exhibit 10.3) to understand resale timelines.
- Monitor the effective date of the registration statements to determine the start of the 45-day issuance blackout period.
- Check subsequent filings for the exact number of shares issued in the Private Placement, as the filing notes shares are subject to beneficial ownership blockers.